A scoping review of 58 studies on Menopause monitoring found that 44 used both laboratory and free-living monitoring, suggesting the field is moving toward more real-world, continuous symptom tracking. The review, based on searches of Web of Science, Scopus, and PubMed through December 2025, also found that AI and data-driven methods remain limited by inconsistent ground truth, small datasets, and a heavy focus on vasomotor symptoms.

Why It Matters To Your Practice

• Most menopause assessment still depends on episodic self-report, which can miss symptom variability and day-to-day context.

• Free-living monitoring may better capture how symptoms affect sleep, activity, function, and quality of life outside the clinic.

• For clinicians interested in AI-enabled care, this review suggests the technology pipeline is active but not yet standardized enough for broad clinical adoption.

Clinical Implications

• Wearables and digital tools may eventually support more objective tracking of vasomotor symptoms, sleep disruption, activity patterns, and physiologic changes.

• Current evidence does not support overinterpreting heart rate variability as a reliable standalone marker of symptom severity, given weak and inconsistent associations.

• Environmental exposures appear more useful as contextual modifiers than as primary diagnostic signals.

• If integrating patient-generated data into care, clinicians should ask how symptoms were labeled, what reference standard was used, and whether validation occurred in real-world settings.

Insights

• The 58 included studies spanned skin thermal and physiologic sensors, digital diaries, ECG and heart rate variability, actigraphy, electromyography, EEG, polysomnography, and environmental sensing.

• Only 14 studies were exclusively laboratory-based, while 44 included free-living monitoring, indicating a shift toward ecologically valid data collection.

• A major bottleneck is the lack of standardized ground truth: studies used inconsistent self-reports, physiologic thresholds, and expert-labeled events.

• Progress is also constrained by small datasets, inconsistent validation methods, and narrow concentration on vasomotor symptoms rather than the broader menopause experience.

The Bottom Line

• AI for menopause monitoring is promising, especially when paired with multimodal, free-living sensing.

• But before these tools meaningfully affect practice, the field needs better labels, larger real-world datasets, and stronger validation across diverse symptom profiles.